

Yuta Sekino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1861720/publications.pdf>

Version: 2024-02-01

13
papers

88
citations

1684188
5
h-index

1474206
9
g-index

14
all docs

14
docs citations

14
times ranked

81
citing authors

#	ARTICLE	IF	CITATIONS
1	Bladder preservation therapy for muscle invasive bladder cancer: the past, present and future. Japanese Journal of Clinical Oncology, 2020, 50, 1097-1107.	1.3	19
2	Proton beam therapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. Journal of Cancer Research and Clinical Oncology, 2020, 146, 711-720.	2.5	15
3	Proton Beam Therapy for Histologically or Clinically Diagnosed Stage I Non-Small Cell Lung Cancer (NSCLC): The First Nationwide Retrospective Study in Japan. International Journal of Radiation Oncology Biology Physics, 2020, 106, 82-89.	0.8	14
4	A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study). Clinical Lung Cancer, 2022, 23, e285-e288.	2.6	12
5	Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: Multi-institutional research in Japan. Clinical and Translational Radiation Oncology, 2021, 29, 54-59.	1.7	6
6	Angiographic Findings in Patients with Hepatocellular Carcinoma Previously Treated Using Proton Beam Therapy. Journal of Oncology, 2019, 2019, 1-7.	1.3	4
7	DIFFERENCE IN DEGREE OF SUB-LETHAL DAMAGE RECOVERY BETWEEN CLINICAL PROTON BEAMS AND X-RAYS. Radiation Protection Dosimetry, 2019, 183, 93-97.	0.8	4
8	Proton beam therapy for renal pelvis and ureter cancer: A report of 5 cases and a literature review. Molecular and Clinical Oncology, 2019, 11, 24-30.	1.0	4
9	Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART) – A study protocol for an open-label, phase II, multicenter study. Contemporary Clinical Trials Communications, 2021, 21, 100724.	1.1	3
10	Acute toxicity and patient-reported symptom score after conventional versus moderately hypofractionated proton therapy for prostate cancer. Journal of Medical Radiation Sciences, 2022, 69, 198-207.	1.5	3
11	Indicator for local recurrence of hepatocellular carcinoma after proton beam therapy: analysis of attenuation difference between the irradiated tumor and liver parenchyma on contrast enhancement CT. British Journal of Radiology, 2020, 93, 20190375.	2.2	2
12	Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma. Journal of Radiation Research, 2021, 62, 682-687.	1.6	2
13	Capacity of proton beams in preserving normal liver tissue during proton beam therapy for hepatocellular carcinoma. Journal of Radiation Research, 2021, 62, 133-141.	1.6	0